Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345599 | 0.75 | NPC1 (0.41) | HTR2AHTR2CHTR2BCYP2A6PIM1 | |
| SCHEMBL1345691 | 0.73 | PDK2 (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL29702997 | 0.69 | CYP17A1 (0.43) | CYP2A6 | |
| SCHEMBL1547757 | 0.64 | ALDH1A1 (0.43) | TRPA1 | |
| SCHEMBL2919380 | 0.64 | ALDH1A1 (0.36) | HTR2AHTR2CTRPA1PDE5A | |
| SCHEMBL391666 | 0.64 | CYP2A6 (0.38) | HTR2AHTR2BBRD4CYP2A6PIM1 | |
| SCHEMBL13319523 | 0.64 | CYP2A6 (0.43) | HTR2AHTR2CCYP2A6PIM1 | |
| SCHEMBL3792044 | 0.62 | CYP2A6 (0.42) | CYP2A6 | |
| SCHEMBL4439252 | 0.62 | ATR (0.37) | HTR2AHTR2CHTR2BCYP2A6 | |
| SCHEMBL22336266 | 0.62 | HTR2A (0.37) | HTR2AHTR2CHTR2BCYP2A6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | HTR2A 2804/4885HTR2C 2055/4885HTR2B 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.